Push-dose pressors can briefly support blood pressure in an adult with a pulse and immediately dangerous hypotension while the team treats the cause and prepares an indicated infusion. They do not restore blood volume, oxygen-carrying capacity or relieve obstruction. This is selected rescue treatment, not routine prophylaxis for every intubation, and it has no established ED survival benefit. Pediatric resuscitation, cardiac arrest and initial anaphylaxis treatment require their own pathways.
Think beyond the cuff pressure. Vasoconstriction can raise pressure while stroke volume falls, especially when a failing ventricle faces more afterload. Phenylephrine provides alpha-mediated vasoconstriction and may cause reflex bradycardia; epinephrine adds beta effects that may support contractility but also increase tachyarrhythmia and myocardial ischemia risk. Reassess perfusion and the shock mechanism rather than choosing a drug from heart rate alone. Phenylephrine label; epinephrine label.
When push-dose pressors may help
Choosing a pressor: shock physiology and cautions
Heart rate alone should not determine pressor choice. Unstable bradycardia requires its resuscitation pathway, and a causal unstable tachyarrhythmia needs prompt rhythm treatment. For acute hypotension with obstructive HCM that does not respond to appropriate fluid administration, phenylephrine or another vasoconstrictor without inotropic activity may be appropriate. AHA adult ALS; HCM guideline.
Preventing push-dose pressor medication errors
Prevent concentration errors: Express epinephrine concentrations in mg/mL or mcg/mL rather than ratios. 1 mg/mL and 0.1 mg/mL (100 mcg/mL) differ tenfold. If the local push-dose protocol specifies 10 mcg/mL, neither stock strength is the final preparation. Prefer pharmacy-prepared, standardized, clearly labeled, ready-to-administer syringes. A prefilled syringe is not necessarily a push-dose syringe. Independently check and read back the drug, dose in mcg, concentration, volume in mL and intended IV route. Use a locally validated preparation and regimen; do not improvise dilution or draw a bolus from an infusion bag without an explicitly approved pharmacy protocol. 0.1 mg/mL product strength; 1 mg/mL product strength; FDA medication-error review.
Monitor every response: Use continuous ECG and oxygen-saturation monitoring, check blood pressure immediately after each bolus and frequently while unstable, and reassess mental status and peripheral perfusion. Confirm IV patency and inspect the site. Pain, swelling or blanching requires stopping administration through that line and urgent assessment under the local extravasation protocol. Watch for excessive hypertension, arrhythmia, ischemia or bradycardia. Repeated or escalating requirements should trigger immediate reassessment and sustained support, not an automatic series of pushes.
What the ED evidence supports
The benefit is brief pressure support; patient-centered outcome benefit remains uncertain. In a single-center chart/video review of 249 ED patients, 19% had dosing or documentation errors, 3% received an overdose, and 39% had an adverse hemodynamic event. These overlapping categories are not additive. The observational design cannot establish causation or prove one pressor safer than another.
A 2025 multisite retrospective cohort included 386 ED patients receiving prefilled epinephrine 100 mcg/10 mL syringes. Subsequently, 70.2% required a continuous vasopressor infusion. This describes practice and reinforces preparation for sustained support; it does not prove that prefilled syringes eliminate errors or improve survival.
At the bedside: Use the few moments of pressure support to deliver cause-directed treatment and establish the indicated infusion. A better blood-pressure reading is reassuring only when the overall perfusion assessment also improves. For complementary adult rescue considerations, see push-dose pressors: key uses in emergency medicine.
